Case Presentation: 74-Year-Old Man With Relapsed/Refractory Follicular Lymphoma
Kami Maddocks, MD, presents the patient diagnosis and treatment history of a 74-year-old-man with relapsed/refractory follicular lymphoma.
Kami Maddocks, MD, presents the patient diagnosis and treatment history of a 74-year-old-man with relapsed/refractory follicular lymphoma.
Stephen M. Ansell, MD, PhD, discusses how immunotherapy is being integrated into treatment for patients with advanced stage Hodgkin lymphoma.
In an interview with Targeted Oncology, Courtney Van Houzen, PharmD, shared her experience in bringing bispecific antibody treatments to a community setting.
Nazli Dizman, MD, discussed the current measures for enforcing ASCO’s language of respect guidelines in the renal cell carcinoma space.
Panelists discuss how unmet needs persist in first-line treatment of metastatic renal cell carcinoma, exploring anticipated advances in tyrosine kinase inhibitor–based therapies and other novel…
Here is a look back on all the FDA happenings from the month of October 2024.
Following its initial approval at 150 mg, trastuzumab-strf has also been approved at 420 mg for the treatment of several HER2-overexpressing cancers.
Erika Hamilton, MD, discusses how to approach treatment after progression on first-line therapy and hormone receptor-positive breast cancer.
During a Case-Based Roundtable® event, Yazan Madanat, MD, discussed a the patient population and outcomes of the COMMANDS trial of luspatercept in myelodysplastic syndrome in…
Ariel Lopez-Chavez, MD, provides an overview of the most promising advancements in targeted therapies for the treatment of small cell lung cancer.
In this episode of Targeted Talks, Seth Wander, MD, PhD, discusses the clinical importance of ESR1 mutations in HR-positive metastatic breast cancer and how these…